In recent years, several novel drugs, rituximab and thrombopoietin receptor agonists (TPO-RAs), such as romiplostim, eltrombopag, avatrombopag, have been developed and applied in the management of ITP.6 Here, TPO is linked to autoimmune thrombocytopenic purpura.